News for Alexion Pharmaceuticals, Inc. (0QZM.L)

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines fo

On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a significant transaction by acquiring 2,722,987 shares of ZimVie Inc at a trad

On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,197,987 shares of PTC Therapeutics Inc.

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and

Labcorp Holdings Inc. (LH) has announced a significant change in its executive leadership team. On November 15, 2024, Glenn Eisenberg, the company's Executive

An increase in the prevalence and misdiagnosis of rare diseases has led to an increase in the sales of orphan drugs....

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Visiongain has published a new report entitled Rare Diseases Market Report 2024-2034: Forecasts by Diseases (Cancer, Metabolic Diseases, Neurological...

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from...

Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial ...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Rapid development and innovation in light therapy technologies and growing patient’s preference toward non-invasive procedures are key factors driving...

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial...

A Pfizer exec tipping a COVID drug's success, a cop, a man breaking into a girlfriend’s laptop and investors in Trump’s media group deal all are charged.

Global Alpers Disease Treatment Market Size Poised To Reflect USD 1.90 billion Billion Mark by 2030. The key market players are listed in the report with...

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the...

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases...